Latest

Leading experts in immuno-oncology discuss next generation cancer vaccines - the most important recent advance in oncology

Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth

Coherus sells its last biosimilar Udenyca to Intas for up to $558M as company homes in on novel cancer meds

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Cellworks Personalized Therapy Biosimulation Study Produces Superior OS and DFS Predictions for Gastroesophageal Cancer Patients

CalciMedica Announces Presentation of a Preclinical Study of Auxora in Acute Kidney Injury at the AKI & CRRT Conference

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for Treatment of Severe Acute Kidney Injury

CalciMedica Announces Private Placement of up to Approximately $55 Million